PUBLISHER: TechSci Research | PRODUCT CODE: 2045917
PUBLISHER: TechSci Research | PRODUCT CODE: 2045917
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The Global DNA and RNA Sample Extraction and Isolation Market is projected to increase from USD 2.83 Billion in 2025 to USD 4.21 Billion by 2031, expanding at a CAGR of 6.84%. This sector focuses on purifying nucleic acids from biological samples to support precise genomic analysis and molecular testing. Primary growth drivers include the integration of precision medicine into clinical workflows, increased funding for life sciences research, and the rising incidence of infectious and genetic diseases. For instance, the American Cancer Society anticipates over two million new cancer cases in the United States in 2024, underscoring the critical need for robust diagnostic tools.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 2.83 Billion |
| Market Size 2031 | USD 4.21 Billion |
| CAGR 2026-2031 | 6.84% |
| Fastest Growing Segment | Pharmaceutical and Biotechnology Companies |
| Largest Market | North America |
However, market expansion is hindered by the high capital costs associated with automated extraction instruments. This financial barrier limits the adoption of automated solutions in smaller laboratories and developing regions where budgets are constrained. Consequently, these facilities often depend on labor-intensive manual methods, which can reduce overall efficiency and scalability in global genomic initiatives.
Market Driver
The increasing global prevalence of genetic disorders and infectious diseases serves as a primary growth accelerator for the market. As the burden of viral infections and chronic conditions rises, there is a parallel demand for accurate molecular diagnostics reliant on high-quality nucleic acid purification. The World Health Organization's 'Global Hepatitis Report 2024' estimated that in 2022, approximately 254 million people were living with hepatitis B and 50 million with hepatitis C. This widespread disease incidence necessitates the increased use of commercial extraction kits to handle high volumes of biological specimens for public health management.
Simultaneously, substantial public and private funding for life sciences R&D provides the financial foundation for market accessibility and technological innovation. Investments allow industry leaders to create efficient platforms and enable laboratories to acquire them despite high costs. For example, Thermo Fisher Scientific invested $1.3 billion in R&D in 2023 to advance technology across its segments. Additionally, Danaher Corporation's subsidiary Cepheid reported roughly $650 million in respiratory testing revenue in the fourth quarter of 2023, highlighting the significant commercial value of molecular testing workflows dependent on effective sample preparation.
Market Challenge
A major barrier to the global market's expansion is the substantial capital investment required for automated extraction instruments. Smaller academic institutions and laboratories in developing regions often operate with limited budgets that cannot support the purchase of high-throughput purification platforms. This financial constraint forces reliance on manual extraction techniques, which are more time-consuming and variable than automated alternatives, thereby creating bottlenecks and limiting the throughput capacity for processing large sample volumes.
This economic challenge is intensified by broader financial strains within the healthcare sector. In 2024, the American Hospital Association reported that hospital and health system expenses for supplies and equipment had risen by nearly 19 percent over the previous three years. These escalating operational costs reduce the funds available for acquiring new diagnostic technologies. Consequently, the adoption of efficient, automated DNA and RNA isolation systems is slowed, impeding the market's capacity to satisfy the growing demand for rapid genomic analysis.
Market Trends
The market is being reshaped by the development of specialized kits for cell-free DNA (cfDNA) and liquid biopsy as non-invasive diagnostic adoption grows. These applications demand highly efficient extraction technologies to isolate fragmented nucleic acids from blood with high purity, a critical requirement for oncology and reproductive health screening. Highlighting this demand, Natera reported processing approximately 735,800 tests in the first quarter of 2024, a 17.5% increase year-over-year, illustrating the massive scale of cfDNA isolation workflows.
Concurrently, the rise of single-cell genomics is driving the need for sample preparation technologies that preserve RNA integrity at the individual cell level. With researchers focusing on cellular heterogeneity, there is increased demand for protocols that maximize yield from minute inputs while minimizing cell stress. This trend has spurred investment in platforms compatible with microfluidic analysis. For instance, 10x Genomics reported a 20% revenue increase to $618.7 million in 2023, reflecting the broader implementation of single-cell workflows and the associated reliance on specialized sample extraction.
Report Scope
In this report, the Global DNA and RNA Sample Extraction and Isolation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global DNA and RNA Sample Extraction and Isolation Market.
Global DNA and RNA Sample Extraction and Isolation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: